G04be03- sildenafil - sildenafil (citrato) (DrugBank: Sildenafil)
17 diseases告示番号 | 疾患名(ページ内リンク) | 臨床試験数 |
---|---|---|
6 | パーキンソン病 | 0 |
46 | 悪性関節リウマチ | 0 |
50 | 皮膚筋炎/多発性筋炎 | 0 |
51 | 全身性強皮症 | 0 |
85 | 特発性間質性肺炎 | 0 |
86 | 肺動脈性肺高血圧症 | 1 |
90 | 網膜色素変性症 | 0 |
113 | 筋ジストロフィー | 0 |
210 | 単心室症 | 0 |
211 | 左心低形成症候群 | 0 |
212 | 三尖弁閉鎖症 | 0 |
225 | 先天性腎性尿崩症 | 0 |
226 | 間質性膀胱炎(ハンナ型) | 0 |
278 | 巨大リンパ管奇形(頚部顔面病変) | 0 |
294 | 先天性横隔膜ヘルニア | 0 |
299 | 嚢胞性線維症 | 0 |
301 | 黄斑ジストロフィー | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | EUCTR2006-001464-23-IT (EUCTR) | 03/11/2006 | 19/02/2007 | A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS AND ABOVE, WITH PULMONARY ARTERIAL HYPERTENSION PAH - ND | A MULTINATIONAL, MULTICENTRE, RANDOMIZED, DOUBLE-BLIND STUDY TO ASSESS THE EFFICACY AND SAFETY OF ORAL SILDENAFIL 20MG TID OR PLACEBO WHEN ADDED TO BOSENTAN IN THE TREATMENT OF SUBJECTS, AGED 18 YEARS AND ABOVE, WITH PULMONARY ARTERIAL HYPERTENSION PAH - ND | Pulmonary Arterial Hypertension PAH . MedDRA version: 6.1;Level: PT;Classification code 10037400 | Trade Name: G04BE03- Sildenafil - sildenafil (citrato) Product Name: Sildenafil INN or Proposed INN: Sildenafil | PFIZER | NULL | Not Recruiting | Female: yes Male: yes | 106 | Czech Republic;Greece;Germany;United Kingdom;Italy |